In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xoma Corp.

www.xoma.com

Latest From Xoma Corp.

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown

Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.

Financing Business Strategies

Finance Watch: Lots Of Money, Big And Small, Flowing Into Drug Development

Big venture capital bets continue in biopharma, including Foresite's new $668m fund and Merck's $125m investment in Moderna, but small VC rounds could be making a comeback. In public company financings, Aslan and Evelo launched in the US, while Ascletis is testing Hong Kong’s IPO market.

Financing StartUps and SMEs

Deals Shaping the Medical Industry, January 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Deals BioPharmaceutical

Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy

Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Xoma Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Xoma Corp.
  • Senior Management
  • James R Neal, CEO
    Tom Burns, SVP, Fin. & CFO
    Kirk Johnson, PhD, VP, Dev.
    Dee Datta, PhD, CBO
  • Contact Info
  • Xoma Corp.
    Phone: (510) 204-7200
    2910 Seventh St.
    Berkeley, CA 94710
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register